히오신 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the hyoscine market size was valued at USD 464.65 million in 2025 and estimated to grow from USD 486.87 million in 2026 to reach USD 614.91 million by 2031, at a CAGR of 4.78% during the forecast period (2026-2031).

This report is Segmented by Dosage Form (Tablets, Injection, Transdermal Patch, Oral Solutions, Others), Indication (Motion Sickness, Gastrointestinal Disorders, Post-Operative Nausea & Vomiting, Neurological Disorders, Respiratory Disorders, Others), End User (Hospitals, Clinics, Home-Care Settings, Others), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Hyoscine Market Trends and Insights

Rising Incidence of Motion Sickness

Growing passenger kilometres by air, sea, and autonomous vehicles heighten vestibular conflicts that precipitate motion sickness. Transdermal scopolamine delivers up to 72-hour prophylaxis, outperforming shorter-acting orals and supporting premium pricing in the hyoscine market. Military programs exploring intranasal formats underscore new mission-critical niches. With tourism rebounding and virtual reality headsets becoming mainstream, the addressable base widens further.

Surge in Surgical Procedures Leading to PONV

Minimally invasive and day-case surgeries are rising, yet PONV still affects up to 30% of general cases and over 50% of high-risk cohorts. Muscarinic blockade complements serotonin antagonists, delivering additive symptom control and shorter recovery stays. Evidence of safety in breastfeeding mothers following caesarean section broadens use in obstetric theatres.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Prevalence of Gastrointestinal Disorders
2. Adoption of Advanced Transdermal Delivery Systems
3. Anticholinergic Side-Effect Profile
4. Stringent Prescription & Regulatory Controls

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Tablets led 2025 revenue with 36.74% hyoscine market share following decades of physician familiarity and low unit cost. However, transdermal patches are projected to clock 6.37% CAGR and could capture a larger slice of the hyoscine market size as sustained-release formats gain favour among travellers and elderly users.

Injection formats retain relevance in emergency departments that value rapid onset, yet adoption outside hospital walls remains modest due to administration complexity. Oral solutions serve paediatric and dysphagic cohorts, while pipeline nasal gels target military and spaceflight settings. Overall, patch technology is propelling differentiation within the hyoscine market through longer dwell times and adherence-friendly designs.

Complete Report Scope:

• By Dosage Form (Value)
  • Tablets
  • Injection
  • Transdermal Patch
  • Oral Solutions
  • Others
• By Indication (Value)
  • Motion Sickness
  • Gastrointestinal Disorders
  • Post-operative Nausea & Vomiting (PONV)
  • Neurological Disorders
  • Respiratory Disorders
  • Others
• By End User (Value)
  • Hospitals
  • Clinics
  • Home-care Settings
  • Others
• By Geography (Value)
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America generated 41.68% of 2025 revenue due to entrenched reimbursement and early adoption of controlled-release formats. Europe follows closely, buoyed by older demographics and stringent PONV guidelines that specify anticholinergic combinations. North American suppliers also benefit from captive Duboisia plantations that buffer botanical supply risk.

Asia-Pacific is forecast to post the highest 7.81% CAGR, lifted by improving diagnostic penetration, rising medical tourism, and government drives to localise active pharmaceutical ingredient production. India's regulatory overhauls, including fast-track plant clearances and pharmacovigilance digitisation, are fostering capacity additions and scale that can reshape the hyoscine market.

Latin America and Middle East & Africa offer longer-term optionality but remain sensitive to price ceilings and patch import tariffs. Multinationals leverage partnered distribution and tiered-pricing to maintain presence, yet supply interruptions from climatic Duboisia shocks can impede service levels. Geographic diversification of plantations is therefore a strategic hedge for the hyoscine market.

1. Perrigo Company
2. Alchem International Pvt Ltd
3. Alkaloids of Australia Pty Ltd
4. Alvogen Group
5. Myungmoon Pharmaceutical Co., Ltd.
6. Boehringer Ingelheim
7. Alkem Laboratories Ltd.
8. Ruwex Pharma BV
9. Sinochem Ningbo Ltd.
10. Phyto Myco Research Corp.
11. Indena S.p.A.
12. Zydus Group
13. MYLAN TECHNOLOGIES
14. ZYDUS PHARMS
15. AMNEALS PHARMS
16. Baxter

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising incidence of motion sickness
  • 4.2.2 Growing prevalence of gastrointestinal disorders
  • 4.2.3 Surge in surgical procedures leading to PONV
  • 4.2.4 Adoption of advanced transdermal delivery systems
  • 4.2.5 Experimental use in neuro-psychiatric disorders
  • 4.2.6 Bio-engineered Duboisia cultivation boosting supply
• 4.3 Market Restraints
  • 4.3.1 Anticholinergic side-effect profile
  • 4.3.2 Stringent prescription & regulatory controls
  • 4.3.3 Duboisia crop volatility due to climate change
  • 4.3.4 Geriatric formulary exclusion trends
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Dosage Form (Value)
  • 5.1.1 Tablets
  • 5.1.2 Injection
  • 5.1.3 Transdermal Patch
  • 5.1.4 Oral Solutions
  • 5.1.5 Others
• 5.2 By Indication (Value)
  • 5.2.1 Motion Sickness
  • 5.2.2 Gastrointestinal Disorders
  • 5.2.3 Post-operative Nausea & Vomiting (PONV)
  • 5.2.4 Neurological Disorders
  • 5.2.5 Respiratory Disorders
  • 5.2.6 Others
• 5.3 By End User (Value)
  • 5.3.1 Hospitals
  • 5.3.2 Clinics
  • 5.3.3 Home-care Settings
  • 5.3.4 Others
• 5.4 By Geography (Value)
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 India
    • 5.4.3.3 Japan
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 South America
    • 5.4.4.1 Brazil
    • 5.4.4.2 Argentina
    • 5.4.4.3 Rest of South America
  • 5.4.5 Middle East and Africa
    • 5.4.5.1 GCC
    • 5.4.5.2 South Africa
    • 5.4.5.3 Rest of Middle East and Africa

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Perrigo Company plc
  • 6.3.2 Alchem International Pvt Ltd
  • 6.3.3 Alkaloids of Australia Pty Ltd
  • 6.3.4 Alvogen Group
  • 6.3.5 Myungmoon Pharmaceutical Co., Ltd.
  • 6.3.6 Boehringer Ingelheim International GmbH
  • 6.3.7 Alkem Laboratories Ltd.
  • 6.3.8 Ruwex Pharma BV
  • 6.3.9 Sinochem Ningbo Ltd.
  • 6.3.10 Phyto Myco Research Corp.
  • 6.3.11 Indena S.p.A.
  • 6.3.12 Cadila Healthcare Ltd.
  • 6.3.13 MYLAN TECHNOLOGIES
  • 6.3.14 ZYDUS PHARMS
  • 6.3.15 AMNEALS PHARMS
  • 6.3.16 Baxter International

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment